Intensive Care Unit 13i2

• monitoring patients with borderline organ function with a view to preventing subsequent multiple organ failure from leading to extremely poor prognosis (early countermeasures in the event of imminent threat to life).
• supporting organ functions (life support) in the event of life-threatening organ failure (e.g. respirator therapy for acute lung failure, catecholamine therapy for circulatory failure, etc.). Artificial organ replacement treatments (e.g. ECMO or ECCO2-R for lung failure, haemofiltration or dialysis for kidney failure) are also available for this purpose

Intensive Care Unit 13i2 has eight ventilation bays and an intervention area. The central laboratory and the ward’s own lab, echocardiography equipment including TEE probe, various haemodynamic monitoring methods and an endoscopy unit (bronchoscopy and gastroscopy) are available around the clock, and there are also several devices for haemofiltration, extracorporeal membrane oxygenation (ECMO) and interventional lung assist (ILA) therapy. Access to this technical equipment means that all invasive and non-invasive diagnostic and treatment measures can be carried out for patients.
Intensive Care Unit 13i2 specifically focuses on severe infectious diseases, haemato-oncological diseases, severe lung failure and extracorporeal gas exchange procedures, both in the field of active patient care and in research. ICU 13i2 has been a registered member of the European Life Support Organisation (ELSO) since 2015.
In addition to clinical work, the Intensive Care Unit also carries out research and teaching, with a specific focus on practical research and clinical implementation of theoretical concepts. While university research is extremely important, activities at the Unit centre on patients and their individual physical and psychological needs.
Information for referring physicians (and contact details for doctors) can be found here.
Intensive Care Unit 13i2 is certified in accordance with EN ISO 9001:2015.